Sunovion is a division of Japan's Sumitomo Dainippon Pharma, which is known for developing a range of neurology and mental health drugs over the last decade or so. Piotr Wnuk 26 June, 2018 ...
The US regulator has approved the first nebulised long-acting muscarinic antagonist for COPD from Sunovion, offering a device that allows patients to breathe normally while taking their medicine.
This includes a novel compound known as SEP-363856, being developed by Sunovion Pharmaceuticals for schizophrenia, which is now in phase 3 clinical trials. The company has a 20-year history in ...
senior director/multichannel marketing at Sunovion Pharmaceuticals. We’re long-term subscribers to WARC and it’s a tool we use extensively. We use it to source case studies and best practice for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results